163 Development of a skin care product that makes your face appear “more cheerful”

Abstract

Ustekinumab is an effective drug against moderate-to-severe psoriasis, but not all patients are responders to therapy and some patients may develop adverse effects. Only two studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab measured by PASI75 at 4 months of treatment (N¼69). The weight was evaluated for response to treatment (PASI75) and a higher weight was obtained in nonresponders than responders (p¼0.018). In addition, the adjusted results (FDR) showed an association between 5 SNPs in TNFRSF1A, HTR2A, NFKBIA, ADAM33, and IL13 genes and poor response to ustekinumab. Furthermore, 6 SNPs in CHUK, C17orf51, ZNF816A, STAT4, SLC22A4, and Corf72 genes were associated with better response to ustekinumab. However, there was not significant association between response to ustekinumab and SNPs in HLA-C as has been recently described.